ClinicalTrials.gg
Status unknownNCT03826277VIMELUpdated Apr 26, 2023

Efficacy of Melanostop Peeling for Improvement of Melasma

An interventional study of Melanostop peel in Melasma, sponsored by VIST - Faculty of Applied Sciences. Status unknown at 1 site in Slovenia. Open to female participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-26.

Sponsored by VIST - Faculty of Applied Sciences · Not applicable, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
20 Years to 50 Years
Sex
Female
01

Study summary

Participants with face melasma will receive 4 Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol and 6% phytic acid. Peels will be performed at 2-week interval. They will also receive a facial tonic and cream for at home use, containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid. They will also receive sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR. Products for at home use will be used twice a day, every day. Measurements will be made at baseline, on the day of the forth peel treatment and 4 weeks after the last peel. Measured parameters will be: mMASI score, VisioFace photography analysis, melasma area measurements, and melanin index, ΔE, CIELab colour measurements with Cortex SkinLab Combo (Cortex Technology Asp, Denmark).

02

Conditions studied

  • Melasma

Browse trials for

03

In context

Melanosis

159 studies on the registry are indexed under Melanosis; 42 are open to participants now.

This study's enrollment of 10 is below the median of 40 across 149 interventional studies indexed under Melanosis.

Browse Melanosis studies →

Lead sponsor

VIST - Faculty of Applied Sciences is the lead sponsor of 13 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult women aged between 20-50 years old.
  • Melasma on the face
  • Fitzpatrick phototypes I-IV
  • Presenting facial melasma
  • In good health condition

Exclusion criteria

Exclusion Criteria:

  • Breastfeeding and pregnancy
  • Women presenting oral herpes
  • Other skin diseases, arthritis, diabetes, diseases of thyroid gland
  • Any known allergies to ingredients of the products used in the study
  • Systemic or topical use of corticosteroids in the previous 6 months
  • Antiaging or lightening cosmetic/estetic procedures in the last 2 months (for example: laser or IPL treatments, chemical peels,..)
  • Taking drugs for skin lightening in the previous 2 months
  • Smoking
  • Lesions of unknown origin
  • Oral or topical use of isotretinoin in the previous 6 months
  • Active bacterial, viral or fungal infections of the skin
  • Presence of keloid scars
  • Immunodeficiency
  • Moderate to severe acne
  • Planned change in hormonal contraception or taking drugs that have an affect on hormonal balance during the course of the study
  • Unrealistic expectations
  • Refusal to use sunscreen protection and complying with instructions
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Melanostop peel treatment group

    * Adult women aged between 20-50 years old. * Melasma on the face * Fitzpatrick phototypes I-IV * Presenting facial melasma * In good health condition

    Other: Melanostop peel

Interventions

  • OtherMelanostop peel

    Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily): * a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid, * sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR

06

What researchers measure

Primary outcomes

  1. Modified Melasma Area and Severity Index (mMASI)

    Melasma severity will be evaluated according to Modified Melasma Area and Severity Index (mMASI). Significant change of the mMASI score from baseline is expected bfore 4th and one month after 4th Melanostop peel treatments. mMASI score is calculated by first assesing the hyperpigmented area of the face. Four areas are evaluated: forehead (F), right malar region (RM), left malar region(LM), and chin (C), corresponding to 30%, 30%, 30% and 10% of the total face. The melasma in each of the four areas is given a numerical value by rating darkness (D) and area of involvement (A). Scoring system: Area of involvement (A), rated 0 to 6: 0= absent; 1 = \<10%; 2 = 10% to 29%; 3 = 30% to 49%; 4= 50% to 69%; 5= 70% to 89%; 6= 90% to 100%. Darkness (D), rated 0 to 4: 0= absent; 1= slight; 2= mild; 3= marked; 4= severe. mMASI total score = (0,3 x A(F) x D(F) ) + (0,3 x A(LM) x D(LM)) + (0,3 x A(RM) x D(RM)) + (0,1 x A(C) x D(C)) Total mMASI score range: 0 - 24

    Time frame: week 1, week 7, week 11

  2. Colour difference

    CIE Lab colour will be measured within the lesion and on the control area outside of the lesion using Cortex Dermalab Combo and colour difference (delta E) will be calculated between the areas and in comparison to baseline values. Significant change of the melasma colour from baseline and in comparison to control area is expected after 4 Melanostop peel treatments.

    Time frame: week 1, week 7, week 11

  3. Melanin index change

    Melanin index will be measured within the lesion and on the control area outside of the lesion using Cortex Dermalab Combo Skin colour probe. Melanin index is given on a scale 0.0-99.9. Significant change of the melanin index from baseline and in comparison to control area is expected before 4th Melanostop peel treatments and 4 weeks after last treatment.

    Time frame: week 1, week 7, week 11

  4. Area of the melasma

    Melasma area will be measured using Visioface photography analysis. Significant change of the melasma area from baseline is expected before 4th Melanostop peel treatments and 4 weeks after last treatment.

    Time frame: week 1, week 7, week 11

07

Study locations

1 site
  • Higher School of Applied Sciences, Institute of Cosmetics
    Ljubljana, 1000, Slovenia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03826277
Lead sponsor
VIST - Faculty of Applied Sciences
Responsible party
Sponsor
First posted
Feb 1, 2019
Start date
Feb 1, 2019
Primary completion
Aug 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Apr 26, 2023

Study contacts

Katja Žmitek, PhD
study chair · Head of Reasearch Group

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion